The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trialAdriaan A. Voors, Piotr Ponikowski, Christiane E. Angermann et al.|Nature Medicine|2022Cited by 889
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical TrialsKaren A. Hicks, Robert J. Temple, Kenneth Rosenfield et al.|Circulation|2018Cited by 712
Warfarin and Aspirin in Patients with Heart Failure and Sinus RhythmShunichi Homma, Richard Buchsbaum, John L.P. Thompson et al.|New England Journal of Medicine|2012Cited by 580
Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection FractionMilton Packer, Faı̈ez Zannad, Stefan D. Anker et al.|Circulation|2020Cited by 422
Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved TrialMilton Packer, Javed Butler, Faı̈ez Zannad et al.|Circulation|2021Cited by 343